

Table S1: Number of patients per country included in the final database

Region	Country	Frequency	Percentage overall	Percentage per region
Southern Africa	Zambia	104,263	50.72	74.91
	South Africa	26,023	12.66	18.70
	Malawi	5,995	2.92	4.31
	Zimbabwe	2,063	1.00	1.48
	Botswana	675	0.33	0.48
	Mozambique	155	0.08	0.11
	<i>Total Southern Africa</i>	<i>139,174</i>	<i>67.70</i>	
West Africa	Cote d'Ivoire	7,294	3.55	42.40
	Nigeria	5,799	2.82	33.71
	Mali	1,705	0.83	9.91
	Burkina Faso	796	0.39	4.63
	Benin	783	0.38	4.55
	Senegal	728	0.35	4.23
	Gambia	97	0.05	0.56
	<i>Total West Africa</i>	<i>17,202</i>	<i>8.37</i>	
Central Africa	Cameroon	1,848	0.90	39.32
	Congo	1,802	0.88	38.34
	Burundi	1,050	0.51	22.34
	<i>Total Central Africa</i>	<i>4,700</i>	<i>2.29</i>	
East Africa	Kenya	29,870	14.53	69.70
	Uganda	9,011	4.38	21.03
	Tanzania	3,975	1.93	9.27
	<i>Total East Africa</i>	<i>42,856</i>	<i>20.85</i>	
Asia-Pacific	Thailand	457	0.22	27.88
	India	229	0.11	13.97
	Indonesia	212	0.10	12.93
	Cambodia	210	0.10	12.81
	Malaysia	117	0.06	7.14
	Papua New Guinea	103	0.05	6.28
	China	91	0.04	5.55
	Singapore	81	0.04	4.94
	Taiwan	53	0.03	3.23
	Hong Kong	49	0.02	2.99
	Japan	21	0.01	1.28
	Philippines	9	0.00	0.55
	South Korea	7	0.00	0.43
	<i>Total Asia-Pacific</i>	<i>1,639</i>	<i>0.80</i>	
TOTAL PATIENTS		<i>205,571</i>	<i>100.0</i>	

Table S2: Comparison of patients with height (BMI) available/missing

		Height available		Height missing	
		N	%	N	%
Region (p<0.0001)					
	Asia Pacific	957	0.7	125	0.4
	Central Africa	4325	3.3	88	0.3
	East Africa	28830	22.3	12951	36.3
	Southern Africa	83039	64.1	18223	51.0
	West Africa	12349	9.5	4340	12.2
Gender (p=0.62)					
	Men	49935	38.6	13725	38.4
	Women	79565	61.4	22002	61.6
Age at baseline (years) (p<0.0001)					
	18-30	29658	22.9	7644	21.4
	30-35	29712	22.9	7823	21.9
	35-40	26603	20.5	7305	20.5
	≥40	43527	33.6	12955	36.3
NRTI[^] in the first line regimen (p<0.0001)					
	AZT	26871	20.8	8463	23.7
	D4T	68471	52.9	24682	69.1
	Tenofovir	32005	24.7	2421	6.8
	Other NRTIs*	2153	1.7	161	0.5
NNRTI[#] or PI[®] in the first line regimen (p<0.0001)					
	Efavirenz	43764	33.8	13898	38.9
	Nevirapine	84184	65.0	21203	59.4
	Protease inhibitor	1588	1.2	626	1.8
Baseline clinical stage (p<0.0001)					
	Missing	10495	8.1	6781	19.0
	WHO I/II or CDC A	44288	34.2	8329	23.3
	WHO III or CDC B	62397	48.2	14896	41.7
	WHO IV or AIDS	12320	9.5	5721	16.0
Baseline CD4 count (cells/μL) (p<0.0001)					
	≥200	31513	24.3	6724	18.8
	0-50	19907	15.4	5911	16.5
	50-200	78080	60.3	23092	64.6
Baseline hemoglobinemia (g/dL) (p<0.0001)					
	<7.5	4744	3.7	1331	3.7
	≥10	55150	42.6	12692	35.5
	Unknown	47967	37.0	16440	46.0
	7.5-10	21639	16.7	5264	14.7

[^]NRTI: Nucleoside/Nucleotide reverse transcriptase inhibitor

*Other NRTI's: didanosine, lamivudine, abacavir and emtricitabine

[#]NNRTI: Non-nucleoside reverse transcriptase inhibitor

[®]PI : protease inhibitor

Table S3 : Comparison of patients with change in cd4 cell count available/missing (first year)

		Change in CD4 cell count available		Change in CD4 cell count missing	
		N	%	N	%
Region					
	Asia Pacific	773	1.2	309	0.3
	Central Africa	819	1.3	3594	3.5
	East Africa	14481	22.8	27300	26.8
	Southern Africa	40313	63.6	60949	59.9
	West Africa	7044	11.1	9645	9.5
Gender					
	Men	23881	37.6	39779	39.1
	Women	39549	62.4	62018	60.9
Age at baseline (years)					
	16-30	13024	20.5	22701	22.3
	30-35	14352	22.6	21909	21.5
	35-40	13142	20.7	19784	19.4
	≥40	22912	36.1	37403	36.7
NRTI[^] in the first line regimen					
	AZT	14477	22.8	20857	20.5
	D4T	34693	54.7	58460	57.4
	Tenofovir	13717	21.6	20709	20.3
	Other NRTIs ^{^*}	543	0.9	1771	1.7
NNRTI[#] or PI[§] in the first line regimen					
	Efavirenz	21438	33.8	36224	35.6
	Nevirapine	41063	64.7	64288	63.2
	Protease inhibitor	929	1.5	1285	1.3
Baseline clinical stage					
	WHO I/II or CDC A	21881	34.5	30736	30.2
	WHO III or CDC B	29580	46.6	47713	46.9
	WHO IV or AIDS	5680	9.0	12361	12.1
	Missing	6289	9.9	10987	10.8
Baseline CD4 count (cells/μL)					
	0-50	12433	19.6	12696	12.5
	50-200	35643	56.2	27630	27.1
	≥200	15354	24.2	13629	13.4
	Unknown	0	0	47842	47.0
Baseline hemoglobinemia (g/dL)					
	<7.5	2325	3.7	3750	3.7
	7.5-10	12728	20.1	14175	13.9
	≥10	37004	58.3	30838	30.3
	Unknown	11373	17.9	53034	52.1

[^]NRTI: Nucleoside/Nucleotide reverse transcriptase inhibitor

^{*}Other NRTI's: didanosine, lamivudine, abacavir and emtricitabine

[#]NNRTI: Non-nucleoside reverse transcriptase inhibitor

[§]PI : protease inhibitor

Table S4 : Comparison of patients with change in cd4 cell count available/missing (second year)

		Change in CD4 cell count available		Change in CD4 cell count missing	
		N	%	N	%
Region					
	Asia Pacific	688	1.9	394	0.3
	Central Africa	271	0.7	4142	3.2
	East Africa	8139	22.3	33642	26.1
	Southern Africa	23374	64.0	77888	60.5
	West Africa	4056	11.1	12633	9.8
Gender					
	Men	13547	37.1	50113	38.9
	Women	22981	62.9	78586	61.1
Age at baseline (years)					
	16-30	7236	19.8	28489	22.1
	30-35	8385	23.0	27876	21.7
	35-40	7751	21.2	25175	19.6
	≥40	13156	36.0	47159	36.9
NRTI[^] in the first line regimen					
	AZT	14477	22.8	20857	20.5
	D4T	34693	54.7	58460	57.4
	Tenofovir	13717	21.6	20709	20.3
	Other NRTIs ^{^*}	543	0.9	1771	1.7
NNRTI[#] or PI^ß in the first line regimen					
	Efavirenz	21438	33.8	36224	35.6
	Nevirapine	41063	64.7	64288	63.2
	Protease inhibitor	929	1.5	1285	1.3
Baseline clinical stage					
	WHO I/II or CDC A	12260	33.6	40357	31.4
	WHO III or CDC B	17560	48.1	59733	46.4
	WHO IV or AIDS	3471	9.5	14570	11.3
	Missing	3237	8.9	14039	10.9
Baseline CD4 count (cells/μL)					
	0-50	7512	20.6	17617	13.7
	50-200	20713	56.7	42560	33.1
	≥200	8303	22.7	20680	16.1
	Unknown	0	0	47842	37.2
Baseline hemoglobinemia (g/dL)					
	<7.5	1420	3.9	4655	3.6
	7.5-10	7701	21.1	19202	14.9
	≥10	22097	60.5	45745	35.5
	Unknown	5310	14.5	59097	45.9

[^]NRTI: Nucleoside/Nucleotide reverse transcriptase inhibitor

^{*}Other NRTI's: didanosine, lamivudine, abacavir and emtricitabine

[#]NNRTI: Non-nucleoside reverse transcriptase inhibitor

^ßPI : protease inhibitor